Candidate gene association studies in sporadic Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 14, Issue 1, 2002, Pages 41-54

  Combarros, Onofre ^a   Alvarez Arcaya, A ^a   Sanchez Guerra M ^a   Infante, J ^a   Berciano, J ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Alzheimer's disease; Association study; Candidate genes; Polymorphism; Risk factors

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BLEOMYCIN HYDROLASE; CATHEPSIN D; CHOLINESTERASE; CYSTATIN C; CYTOCHROME P450 2D6; DIHYDROLIPOAMIDE SUCCINYLTRANSFERASE; DIPEPTIDYL CARBOXYPEPTIDASE; FAS ANTIGEN; FLUROTHYL; HLA A2 ANTIGEN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; NITRIC OXIDE SYNTHASE; PRESENILIN 1; PRESENILIN 2; PRION PROTEIN; SEROTONIN TRANSPORTER; TAU PROTEIN; TRANSCRIPTION FACTOR; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ALLELE; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; DNA POLYMORPHISM; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; RISK FACTOR;

EID: 0036278174     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058332     Document Type: Article

References (142)

1. Untangling the genetics of a complex disease
2. Exploring the etiology of Alzheimer disease using molecular genetics
3. Genetic testing for Alzheimer disease. Practical and ethical issues
4. Clinical rationale of genetic testing in dementia
5. Genetic testing and Alzheimer disease: Has the time come?
6. The origins of Alzheimer disease. A is for amyloid
7. The molecular and genetic basis of AD: The end of the beginning
8. SNP association studies in Alzheimer's disease highlight problems for complex disease analysis
9. Association studies of genetic polymorphisms and complex disease
10. Variability and validity of polymorphism association studies in Parkinson's disease
11. Alzheimer's disease genetics: Home runs and strikeouts
12. The future of genetic analysis of neurological disorders
13. In search of perverse polymorphisms
14. Alzheimer's disease, apolipoprotein E4, and gender
15. Gender difference in apolipoprotein-E associated risk for familial Alzheimer disease: A possible clue to the higher incidence of Alzheimer disease in women
16. Alzheimer's disease: Interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset
17. Gender effect on apolipoprotein E ε4 allele-associated risk for sporadic Alzheimer's disease
18. Gene dose of apolipoprotein type 4 allele and the risk of Alzheimer's disease in late onset families
19. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
20. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: Results of an autopsy series and analysis of several combined studies
21. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia
22. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease
23. A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the ε4 allele
24. The -491 AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease
25. Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease
26. The -491 A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: Independent risk and linkage disequilibrium with the known APOE polymorphism
27. APOE promoter polymorphisms do not confer independent risk for Alzheimer's disease in a French population
28. Promoter polymorphism (-491 A/T) in the APOE gene of Finnish Alzheimer's disease patients and control individuals
29. The -491 A/T polymorphism in the regulatory region of the apolipoprotein E gene and early-onset Alzheimer's disease
30. Apolipoprotein E promoter polymorphism and sporadic Alzheimer's disease in a Japanese population
31. High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease
32. Apolipoprotein E promoter and α2-macroglobulin polymorphisms are not genetically associated with Chinese late onset Alzheimer's disease
33. The -491 TT apolipoprotein E promoter polymorphism is associated with reduced risk for sporadic Alzheimer's disease
34. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease
35. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
36. A technical KO of amyloid-β peptide
37. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
38. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease
39. Presenilin-1 polymorphism and Alzheimer's disease
40. Association between a PS-1 intronic polymorphism and late onset Alzheimer's disease
41. Presenilin polymorphisms in Alzheimer's disease
42. Presenilin 1 intronic polymorphism is not associated with Alzheimer type neuropathological changes or sporadic Alzheimer's disease
43. Polymorphisms in the presenilin 1 and presenilin 2 genes and risk for sporadic Alzheimer's disease
44. Case-control study of presenilin-1 intronic polymorphism in sporadic early and late onset Alzheimer's disease
45. The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Aβ load in brain
46. Presenilin-I, presenilin-II, and VLDL-R associations in early onset Alzheimer's disease
47. The α2-macroglobulin gene in AD. A population-based study and meta-analysis
48. α2 macroglobulin and the risk of Alzheimer's disease
49. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
50. Genetic association of an α2-macroglobulin (Val1000Ile) polymorphism and Alzheimer's disease
51. 2-macroglobulin with Alzheimer's disease in a Finnish elderly population
52. Role of the low-density lipoprotein receptor-related protein in β-amyloid metabolism and Alzheimer disease
53. LRP in Alzheimer's disease: Friend or foe?
54. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease
55. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease
56. Association at LRP gene locus with sporadic late-onset Alzheimer's disease
57. Low density lipoprotein receptor-related protein gene polymorphisms and risk for late-onset Alzheimer's disease in a Japanese population
58. Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene
59. The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer's disease
60. Alzheimer's risk associated with human apolipoprotein E, alpha-2 macroglobulin and lipoprotein receptor related protein polymorphisms: Absence of genetic interactions, and modulation by gender
61. Case-control study and meta-analysis of low density lipoprotein receptor-related protein gene exon 3 polymorphism in Alzheimer's disease
62. Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by LDL receptor-related protein pathway
63. Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer's disease
64. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease
65. VLDL receptor polymorphism, cognitive impairment, and dementia
66. Risk of Alzheimer's disease is associated with a very low-density lipoprotein receptor genotype in Northern Ireland
67. Lipoprotein lipase mutations and Alzheimer's disease
68. A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease
69. Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's disease
70. No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease
71. Cathepsin D polymorphism not associated with Alzheimer's disease in Japanese
72. Lack of association between cathepsin D genetic polymorphism and Alzheimer disease in a Spanish sample
73. The genetic association between cathepsin D and Alzheimer's disease
74. The human FE65 gene: Genomic structure and an intronic biallelic polymorphism associated with sporadic dementia of the Alzheimer type
75. A FE65 polymorphism associated with risk of developing sporadic late-onset Alzheimer's disease but not with Aβ loading in brains
76. Evidence against association of the FE65 gene (APBB1) intron 13 polymorphism in Alzheimer's patients
77. No association between an intronic biallelic polymorphism of the FE65 gene and Alzheimer's disease
78. The transcriptional factor LBP-1c/CP2/LSF gene on chromosome 12 is a genetic determinant of Alzheimer's disease
79. Genetic association of an LBP-1c/CP2/LSF gene polymorphism with late onset Alzheimer's disease
80. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease
81. Association between bleomycin hydrolase and Alzheimer's disease in Caucasians
82. Lack of association between bleomycin hydrolase gene polymorphism and Alzheimer's disease in Japanese people
83. APOE 4-associated Alzheimer's disease risk is modified by alpha-1-antichymotrypsin polymorphism
84. Apolipoprotein E and alpha-1 antichymotrypsin polymorphism genotyping in Alzheimer's disease and in dementia with Lewy bodies. Distinctions between diseases
85. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia
86. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease
87. Further evidence for a synergistic association between APOE ε4 and BCHE-K in confirmed Alzheimer's disease
88. Butyrylcholinesterase K variant and Alzheimer's disease
89. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease
90. Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease
91. Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients
92. The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women
93. Evidence of a neuronal oxidative damage in Alzheimer's disease
94. The CCTTT polymorphisms in the NOS2A gene is associated with dementia with Lewy bodies
95. Angiotensin converting enzyme and endothelial nitric oxid synthase DNA polymorphisms and late onset Alzheimer's disease
96. Association between Alzheimer's disease and the NOS3 gene
97. Nitric oxide synthase gene polymorphisms in Alzheimer's disease and dementia with Lewy bodies
98. The Glu298Asp polymorphism in the NOS3 gene is not associated with sporadic Alzheimer's disease
99. No association between the NOS3 codon 298 polymorphism and Alzheimer's disease in a sample from the United States
100. NOS3 polymorphism not associated with Alzheimer's disease in Japanese
101. Alzheimer's disease and DLST genotype
102. A DLST genotype associated with reduced risk for Alzheimer's disease
103. Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease
104. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease
105. Association of transferrin C2 allele with late-onset Alzheimer's disease
106. Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease
107. Association of the HLA-A2 allele with an earlier age of onset of Alzheimer's disease
108. HLA class I, II & III genes in confirmed late-onset Alzheimer's disease
109. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists. The Cache county study
110. Interleukin-1 and the immunogenetics of Alzheimer disease
111. Association of an interleukin 1α polymorphism with Alzheimer's disease
112. Association of early-onset Alzheimer's disease with an interleukin-1α gene polymorphism
113. Association of interleukin-1 gene polymorphisms in Alzheimer's disease
114. Lack of association of the interleukin-1α gene polymorphism with Alzheimer's disease in a Korean population
115. Genetic assoication studies of interleukin-1 (IL-1A and IL-1B) and interleukin-1 receptor antagonist genes and the risk of Alzheimer's disease
116. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease
117. 2-macroglobulin influences the risk for Alzheimer's disease
118. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer's disease and vascular dementia: A case-control study
119. Apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: Finding of a positive association for a polymorphism in the TNFRSR6 gene
120. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease
121. Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E ε4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology
122. The angiotensin I converting enzyme gene as a susceptibility factor for dementia
123. A polymorphism in the cystatin C gene is a novel risk for late-onset Alzheimer's disease
124. The cystatin C polymorphism is not associated with early onset Alzheimer's disease
125. A polymorphism in the tau gene associated with risk for Alzheimer's disease
126. Tau gene polymorphisms and apolipoprotein E ε4 may interact to increase risk for Alzheimer's disease
127. Tau polymorphisms are not associated with Alzheimer's disease
128. Genetic studies in Alzheimer's disease with an NACP/α-synuclein polymorphism
129. Genetic association between Alzheimer disease and the alpha-synuclein gene
130. Genetics of prions
131. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease
132. Polymorphism of the prion protein is associated with cognitive impairment in the elderly. The EVA study
133. Polymorphism at codon 129 of the prion protein gene is not associated with sporadic AD
134. Prion protein polymorphism and Alzheimer's disease: One modulatory trait of cognitive decline?
135. Promoter polymorphism of the 5-HT transporter and Alzheimer's disease
136. Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: No evidence for an association
137. Genetic association of estrogen receptor gene polymorphisms with Alzheimer's disease
138. Lack of an association of estrogen receptor α gene polymorphisms and transcriptional activity with Alzheimer disease
139. Association of the estrogen receptor alpha gene polymorphisms with sporadic Alzheimer's disease
140. Estrogen receptor gene polymorphisms in patients with Alzheimer's disease, vascular dementia and alcohol-associated dementia
141. Interaction between estrogen receptor 1 and the epsilon4 allele of apolipoprotein E increases the risk of familial Alzheimer's disease in women
142. Are the estrogen receptors involved in Alzheimer's disease?